Search Videos by Topic or Participant
Browse by Series:

PD-1 Combinations Explored in RCC

Discussant: Brian I. Rini, MD, Cleveland Clinic
Published: Monday, Jan 26, 2015
For High-Definition, Click
Several clinical studies will continue to investigation PD-1 inhibition in renal cell carcinoma, explains Brian I. Rini, MD. A large phase I study showed modest activity with nivolumab as a single-agent, with questions regarding a maximum tolerated dose still lingering.

The next wave of research will focus on combination strategies, specifically looking at nivolumab with a TKI, such as sunitinib or pazopanib. The most intriguing combination involves nivolumab and ipilimumab. This approach has shown promising activity for patients with melanoma, Rini notes.

View the video, to hear the discussion.
Slider Left
Slider Right
For High-Definition, Click
Several clinical studies will continue to investigation PD-1 inhibition in renal cell carcinoma, explains Brian I. Rini, MD. A large phase I study showed modest activity with nivolumab as a single-agent, with questions regarding a maximum tolerated dose still lingering.

The next wave of research will focus on combination strategies, specifically looking at nivolumab with a TKI, such as sunitinib or pazopanib. The most intriguing combination involves nivolumab and ipilimumab. This approach has shown promising activity for patients with melanoma, Rini notes.

View the video, to hear the discussion.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x